Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Overall Status
Recruiting
CT.gov ID
NCT06120244
Collaborator
(none)
120
1
120
1

Study Details

Study Description

Brief Summary

Background:

Infections in the lower respiratory tract (lungs) are the leading cause of death from infectious disease worldwide. This was true even before the COVID-19 pandemic. Respiratory viruses are still a major health threat. Many of these viruses infect people by penetrating the thin skin that lines the nose. These viruses can also spread easily to other people when they multiply in the tissues that line the nose. Researchers want to learn more about what these viruses do inside the nose, how they get from the nose to the lungs, and how they spread from person to person.

Objective:

To collect cell samples from inside the noses of healthy people. These cells will be stored for use in future research on respiratory diseases.

Eligibility:

Healthy volunteers aged 18 years and older.

Design:

Most participants will have 1 visit on 1 day. They will be asked questions. Those who have a runny nose, coughing, congestion, or fever will be asked to wait up to 21 days before participating.

Participants will be given a slender swab with small bristles at the end. They will rub the inside of their nose with the swab. A clinic staff member will be present to help, if needed.

Participants will provide their name, age, and sex. This information will be encoded so that only certain researchers will know the participants identities.

Participants will not be contacted again....

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Study Description:

    This is a repository protocol with prospective sample collection to provide samples needed for future studies of the pathogenesis of emerging respiratory viruses. Nasal brushings will be collected from approximately 100 healthy volunteers at RML and stored in the LV to be made available for future research studies that will be conducted under separate protocols, as applicable.

    Primary Objective:

    To obtain nasal epithelium brushes from healthy volunteers for 1) establishment of upper respiratory tract organoids, 2) assay validation, and 3) use for research into the pathogenesis of emerging respiratory viruses.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    120 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    Establishment of a Biobank of Nasal Epithelium Samples From Healthy Volunteers
    Actual Study Start Date :
    Nov 1, 2023
    Anticipated Primary Completion Date :
    Oct 31, 2033
    Anticipated Study Completion Date :
    Oct 31, 2033

    Arms and Interventions

    Arm Intervention/Treatment
    Healthy Volunteers

    Healthy volunteers aged 18 years and older

    Outcome Measures

    Primary Outcome Measures

    1. To obtain nasal epithelium brushes from healthy volunteers for 1) establishment of upper respiratory tract organoids, 2) assay validation, and 3) use for research into the pathogenesis of emerging respiratory viruses. [10 years]

      To obtain nasal epithelium brushes from healthy volunteers for 1) establishment of upper respiratory tract organoids, 2) assay validation, and 3) use for research into the pathogenesis of emerging respiratory viruses.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    • INCLUSION CRITERIA:

    In order to be eligible to participate in this study, an individual must meet all of the following criteria:

    • Aged >=18 years.

    • Able to provide informed consent.

    • Willing to allow biological samples and data to be stored for future research.

    EXCLUSION CRITERIA:

    An individual who meets any of the following criteria will be excluded from participation in this

    study:

    • History of respiratory symptoms including but not limited to runny nose, coughing, congestion, and/or fever within the past 14 days.

    • NIH and laboratory staff with direct involvement in the operation or maintenance of the repository are excluded from participation.

    • An individual who has any condition that, in the judgment of the investigator, may put them at undue risk or make them unsuitable for participation in the study will be excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Rocky Mountain Laboratories Hamilton Montana United States 59840

    Sponsors and Collaborators

    • National Institute of Allergy and Infectious Diseases (NIAID)

    Investigators

    • Principal Investigator: Emmie de Wit, Ph.D., National Institute of Allergy and Infectious Diseases (NIAID)

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    National Institute of Allergy and Infectious Diseases (NIAID)
    ClinicalTrials.gov Identifier:
    NCT06120244
    Other Study ID Numbers:
    • 10001862
    • 001862-I
    First Posted:
    Nov 7, 2023
    Last Update Posted:
    Nov 10, 2023
    Last Verified:
    Nov 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID)

    Study Results

    No Results Posted as of Nov 10, 2023